Banque Pictet & Cie SA Sells 13,128 Shares of Zoetis Inc. (NYSE:ZTS)

Banque Pictet & Cie SA lessened its stake in Zoetis Inc. (NYSE:ZTS) by 0.5% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,480,863 shares of the company’s stock after selling 13,128 shares during the quarter. Zoetis comprises 3.9% of Banque Pictet & Cie SA’s investment portfolio, making the stock its 6th biggest position. Banque Pictet & Cie SA’s holdings in Zoetis were worth $430,082,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of ZTS. International Assets Investment Management LLC raised its holdings in shares of Zoetis by 40.7% during the 4th quarter. International Assets Investment Management LLC now owns 2,429 shares of the company’s stock worth $479,000 after buying an additional 703 shares in the last quarter. J.W. Cole Advisors Inc. lifted its holdings in shares of Zoetis by 8.3% in the fourth quarter. J.W. Cole Advisors Inc. now owns 1,650 shares of the company’s stock worth $326,000 after acquiring an additional 127 shares during the last quarter. GUNN & Co INVESTMENT MANAGEMENT INC. acquired a new stake in shares of Zoetis in the 4th quarter valued at approximately $217,000. RWA Wealth Partners LLC boosted its stake in shares of Zoetis by 358.6% in the 4th quarter. RWA Wealth Partners LLC now owns 10,645 shares of the company’s stock valued at $2,101,000 after purchasing an additional 8,324 shares in the last quarter. Finally, Larson Financial Group LLC increased its position in Zoetis by 34.7% during the 4th quarter. Larson Financial Group LLC now owns 948 shares of the company’s stock worth $187,000 after purchasing an additional 244 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 0.7 %

Shares of Zoetis stock traded down $1.27 during midday trading on Friday, reaching $180.90. The company had a trading volume of 1,262,412 shares, compared to its average volume of 1,969,611. The stock has a fifty day moving average price of $178.56 and a 200 day moving average price of $174.94. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The firm has a market cap of $81.96 billion, a PE ratio of 34.86, a P/E/G ratio of 2.79 and a beta of 0.86. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. During the same period in the prior year, the firm posted $1.41 EPS. The company’s quarterly revenue was up 8.3% on a year-over-year basis. On average, equities analysts anticipate that Zoetis Inc. will post 5.84 earnings per share for the current year.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of research reports. Stifel Nicolaus boosted their target price on shares of Zoetis from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Monday, August 5th. The Goldman Sachs Group decreased their target price on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a research note on Monday, May 6th. BTIG Research boosted their target price on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Piper Sandler boosted their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and an average price target of $217.11.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.